Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Stader, F.; Decosterd, L.; Stoeckle, M.; Cavassini, M.; Battegay, M.; Saldanha, S.A.; Marzolini, C.; Courlet, P.

doi:10.1097/QAD.0000000000002489

Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Détails

Demande d'une copie

ID Serval

serval:BIB_6666EE49EABD

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Périodique

AIDS

Auteur⸱e⸱s

Stader F., Decosterd L., Stoeckle M., Cavassini M., Battegay M., Saldanha S.A., Marzolini C., Courlet P.

Collaborateur⸱rice⸱s

and the Swiss HIV Cohort Study

ISSN

1473-5571 (Electronic)

ISSN-L

0269-9370

Statut éditorial

Publié

Date de publication

01/05/2020

Peer-reviewed

Oui

Volume

Numéro

Pages

949-952

Langue

anglais

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

: The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH aged at least 55 years. DDI magnitudes were comparable with those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.

Mots-clé

Aged, Aged, 80 and over, Aging, Amlodipine/adverse effects, Amlodipine/therapeutic use, Anti-Retroviral Agents/therapeutic use, Antiretroviral Therapy, Highly Active, Atorvastatin/adverse effects, Atorvastatin/therapeutic use, Cardiovascular Agents/adverse effects, Cardiovascular Agents/therapeutic use, Cardiovascular Diseases/drug therapy, Cardiovascular Diseases/epidemiology, Darunavir/adverse effects, Darunavir/therapeutic use, Drug Interactions, Female, HIV Infections/drug therapy, HIV Infections/epidemiology, Heterocyclic Compounds, 3-Ring/adverse effects, Heterocyclic Compounds, 3-Ring/therapeutic use, Humans, Male, Middle Aged, Oxazines/adverse effects, Oxazines/therapeutic use, Piperazines/adverse effects, Piperazines/therapeutic use, Pyridones/adverse effects, Pyridones/therapeutic use, Rosuvastatin Calcium/adverse effects, Rosuvastatin Calcium/therapeutic use, Treatment Outcome

OAI-PMH

oai:serval.unil.ch:BIB_6666EE49EABD

DOI

10.1097/QAD.0000000000002489

Pubmed

32028327

Web of science

000562484200019

Open Access

Oui

Création de la notice

17/02/2020 15:57